This study is currently not recruiting participants.

IUCRO-0414; A Phase 2 Study of Carfilzomib and Bone Metabolism in Patients With Multiple Myeloma in First Relapse or Refractory to First Line Therapy

Study of Investigational Medication in Multiple Myeloma

Not Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to find out the effects (good and bad) of a drug called carfilzomib on multiple myeloma.

Detailed description of study

This phase II trial studies how well carfilzomib works in treating patients with multiple myeloma in first relapse or refractory to first-line therapy. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Multiple Myeloma
  • Age: 18 years - 100 years
  • Gender: All

The purpose of this study is to investigate how an investigational medication affects multiple myeloma, a type of blood cancer. Multiple myeloma involves cancerous plasma cells in the bone marrow. This study focuses on patients whose cancer has returned after initial treatment or did not respond to the first treatment.

Participants in this study will receive the investigational medication, which may work by stopping cancer cells from growing. The study will monitor the effects of this treatment to understand its potential benefits and side effects.

  • Who can participate: Eligible participants are adults diagnosed with multiple myeloma, specifically those whose cancer has relapsed after initial treatment or did not respond to first-line therapy. Participants must meet specific health criteria and provide informed consent.
  • Study details: Participants will receive the investigational medication to assess its impact on cancer cell growth. The study will carefully monitor participants for any effects, both positive and negative.
Updated on 19 Feb 2024. Study ID: 1306011620

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team